```
L1             1 S US 20090176846/PN

     FILE 'REGISTRY' ENTERED AT 09:33:06 ON 08 OCT 2010
L2             1 S 887396-01-2/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 09:33:22 ON 08 OCT 2010
L3             1 S 75-75-2/RN

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   75-75-2  REGISTRY
CN   Methanesulfonic acid  (CA INDEX NAME)
OTHER NAMES:
CN   MCAT 1201
CN   Methylsulfonic acid
CN   NSC 3718
CN   Scaleva
DR   1129867-34-0, 125756-91-4, 98527-29-8, 115449-98-4, 62203-24-1,
     87128-90-3, 44209-64-5, 44209-72-5
MF   C H4 O3 S
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA,
CAPLUS,
       CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,
DETHERM*,
       EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*,
HSDB*,
       IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA,
PROMT, PS,
       RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2,
USPATFULL,
       USPATOLD
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA  CAplus document type:  Conference; Dissertation; Journal;
Patent; Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological
study);
       FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); PRPH
       (Prophetic); RACT (Reactant or reagent); USES (Uses); NORL (No
role in
       record)
RLD.P  Roles for non-specific derivatives from patents:  ANST
(Analytical
       study); BIOL (Biological study); PREP (Preparation); PROC
(Process); PRP
       (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES
(Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL
(Biological
       study); FORM (Formation, nonpreparative); MSC (Miscellaneous);
OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP
```

(Properties); RACT
(Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents: ANST
(Analytical
study); BIOL (Biological study); CMBI (Combinatorial study);
FORM
(Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC
(Process); PRP (Properties); RACT (Reactant or reagent); USES
(Uses)

SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 09:33:47 ON 08 OCT 2010
L4 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\10584984 10082010 1.str



L5 0 S L4 SSS SAM
L6 18 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:34:25 ON 08 OCT 2010
L7 14 S L6
L8 2 S L6 AND L3

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AB The present invention relates to an oral preparation of N-hydroxy-4-[5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy]benzamidine (I) having improved bioavailability. More particularly, the present invention relates to an oral preparation comprising I or pharmaceutically acceptable salt thereof; and one or more carbonates selected from the group consisting of alkali metal carbonate, alkali metal bicarbonate and alkaline earth metal carbonate, and/or one or more disintegrants selected from the group consisting of sodium starch glycolate,

carmellose calcium and croscarmellose sodium. The oral preparation according to the present invention inhibits gelation of I or pharmaceutically acceptable salt thereof in the early stage of release, which increases dissoln. rate and remarkably raises bioavailability.

ACCESSION NUMBER: 2006:515838 CAPLUS Full-text
DOCUMENT NUMBER: 144:495422
TITLE: An oral preparation having improved bioavailability
INVENTOR(S): Ryu, Jei Man; Cho, Soon Ki; Jung, Se Hyun; Seong, Seung Kyoo; Cho, Eun Hee; Ahn, Seok Hoon; Kim, Yun Jung
PATENT ASSIGNEE(S): Dong Wha Pharmaceutical Ind. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057507	A1	20060601	WO 2005-KR3950	20051122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2006057511	A	20060526	KR 2005-111543	20051122
KR 2006057514	A	20060526	KR 2005-111779	20051122
AU 2005307994	A1	20060601	AU 2005-307994	20051122
AU 2005307994	B2	20090723		

CA 2585003 A1 20060601 CA 2005-2585003
20051122
CA 2585003 C 20100817
EP 1814593 A1 20070808 EP 2005-821036
20051122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 101056658 A 20071017 CN 2005-80038889
20051122
JP 2008520655 T 20080619 JP 2007-542909
20051122
BR 2005017396 A 20081014 BR 2005-17396
20051122
PT 1701722 E 20091210 PT 2005-817697
20051122
ES 2333739 T3 20100226 ES 2005-817697
20051122
CN 101693029 A 20100414 CN 2009-10166667
20051122
ZA 2007000485 A 20071128 ZA 2007-485
20070117
US 20070254930 A1 20071101 US 2007-577469
20070418
ZA 2007004236 A 20081126 ZA 2007-4236
20070524
PRIORITY APPLN. INFO.: KR 2004-96390 A
20041123
CN 2005-80038889 A3
20051122
WO 2005-KR3950 W
20051122
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IPCI A61K0047-30 [I,A]; A61P0019-10 [I,A]; A61P0019-00 [I,C*]
IPCR A61K0047-30 [I,A]; A61K0047-30 [I,C]; A61P0019-00 [I,C]; A61P0019-
10 [I,A]
CC 63-6 (Pharmaceuticals)
IT 491577-61-8
RL: PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use);
BIOL
(Biological study); RACT (Reactant or reagent); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT 873222-99-2 887396-01-2
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL
(Biological
study); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT 75-75-2, Methanesulfonic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT Drug delivery systems
(capsules; oral prepns. containing benzenecarboximidamide
derivative and
carbonates)

IT Drug delivery systems
(granules; oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT Gelation
(inhibition in; oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT Antiosteoporotic agents
Dissolution
Drug bioavailability
(oral prepns. containing benzenecarboximidamide derivative and carbonates)
IT Carbonates
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and carbonates)
IT Drug delivery systems
(tablets; oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT Osteoporosis
(treatment of; oral prepns. containing benzenecarboximidamide derivative and
carbonates)
IT 491577-61-8
RL: PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); BIOL
(Biological study); RACT (Reactant or reagent); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and carbonates)
IT 873222-99-2 887396-01-2
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and carbonates)
IT 75-75-2, Methanesulfonic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(oral prepns. containing benzenecarboximidamide derivative and carbonates)
IT 144-55-8, Sodium bicarbonate, biological studies 298-14-6, Potassium
bicarbonate 471-34-1, Calcium carbonate, biological studies 497-19-8,
Sodium carbonate, biological studies 584-08-7, Potassium carbonate
1309-48-4, Magnesium oxide, biological studies 7758-23-8, Calcium
biphosphate 9050-04-8, Carmellose calcium 9063-38-1, Sodium starch
glycolate 10103-46-5, Calcium phosphate 74811-65-7, Croscarmellose
sodium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral prepns. containing benzenecarboximidamide derivative and carbonates)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AB Disclosed is N-hydroxy-4-[5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy]benzamidine di-methanesulfonic acid salt, which has excellent bioavailability. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound
ACCESSION NUMBER: 2006:513353 CAPLUS Full-text
DOCUMENT NUMBER: 144:495412
TITLE: N-Hydroxy-4-[5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy]benzamidine di-methanesulfonic acid salt
INVENTOR(S): Ryu, Jei, Man; Lee, Jin, Soo; Shin, Dong, Hyuk; Seong, Seung, Kyoo; Cho, Soon, Ki; Jeon, Chan, Seok; Jin, Young, Goo; Lee, Ki, Young; Jung, Se, Hyun; Cho, Eun, Hee
PATENT ASSIGNEE(S): Dong Wha Pharmaceutical Ind. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006057501	A1	20060601	WO 2005-KR3934	20051122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

KR 2006057511 A 20060526 KR 2005-111543 20051122

KR 2006057514 A 20060526 KR 2005-111779 20051122

CA 2552766 A1 20060601 CA 2005-2552766 20051122

CA 2552766 C 20100817

AU 2005300239 A1 20060706 AU 2005-300239 20051122

AU 2005300239 B2 20090806

EP 1701722 A1 20060920 EP 2005-817697 20051122

EP 1701722 B1 20091014

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU

CN 1905871 A 20070131 CN 2005-80001744 20051122

JP 2008508264 T 20080321 JP 2007-523495 20051122

BR 2005014386 A 20080610 BR 2005-14386 20051122

NZ 555725 A 20080731 NZ 2005-555725 20051122

RU 2361867 C2 20090720 RU 2007-123614 20051122

AT 445397 T 20091015 AT 2005-817697 20051122

PT 1701722 E 20091210 PT 2005-817697 20051122

ES 2333739 T3 20100226 ES 2005-817697 20051122

CN 101693029 A 20100414 CN 2009-10166667 20051122

ZA 2007000485 A 20071128 ZA 2007-485 20070117

HK 1094530 A1 20100625 HK 2007-101468 20070208

ZA 2007004236 A 20081126 ZA 2007-4236 20070524

IN 2007DN04653 A 20070817 IN 2007-DN4653 20070618

US 20090176846 A1 20090709 US 2008-584984 20080508

PRIORITY APPLN. INFO.: KR 2004-96390 A 20041123

CN 2005-80038889 A3 20051122

20051122
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IPCI A61K0031-426 [I,A]
IPCR A61K0031-426 [I,A]; A61K0031-426 [I,C]
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 887396-01-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(preparation of stable benzenecarboximidamide derivative methanesulfonate salt
for treating bone diseases and allergic inflammation)
IT 75-75-2, Methanesulfonic acid 491577-61-8, N-Hydroxy-4-[5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy]benzamidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of stable benzenecarboximidamide derivative methanesulfonate salt
for treating bone diseases and allergic inflammation)
IT Inflammation
(allergic, treatment of; preparation of stable benzenecarboximidamide derivative
methanesulfonate salt for treating bone diseases and allergic inflammation)
IT Bone, disease
(fracture, treatment of; preparation of stable benzenecarboximidamide derivative
methanesulfonate salt for treating bone diseases and allergic inflammation)
IT Allergy
(inflammation, treatment of; preparation of stable benzenecarboximidamide
derivative methanesulfonate salt for treating bone diseases and allergic
inflammation)
IT Drug delivery systems
(oral; preparation of stable benzenecarboximidamide derivative methanesulfonate
salt for treating bone diseases and allergic inflammation)
IT Antiosteoporotic agents
Osteoporosis
(preparation of stable benzenecarboximidamide derivative methanesulfonate salt
for treating bone diseases and allergic inflammation)
IT 887396-01-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(preparation of stable benzenecarboximidamide derivative methanesulfonate salt
for treating bone diseases and allergic inflammation)
IT 75-75-2, Methanesulfonic acid 491577-61-8, N-Hydroxy-4-[5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-

yl)phenoxy]pentoxy]benzamidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of stable benzenecarboximidamide derivative methanesulfonate salt
for treating bone diseases and allergic inflammation)